Call Us + 33 1 84 88 31 00

Article R5121-201-4 of the French Public Health Code

The pharmacovigilance carried out on individually prepared advanced therapy medicinal products includes monitoring to ensure traceability between the various stages, from the removal of tissues, cells or blood, where applicable, to the administration of the individually prepared advanced therapy medicinal product to a patient. This traceability also applies to the research referred to in Article L. 1121-1. This traceability supplements the requirements relating to the traceability of tissues and cells…

Read More »

Article R5121-201-5 of the French Public Health Code

I.-Any establishment or body referred to in Article L. 4211-9-1 or any pharmaceutical establishment referred to in Articles L. 5124-1 or L. 5124-9-1 shall set up and keep up to date a system ensuring the traceability of advanced therapy medicinal products prepared on an ad hoc basis. II – Establishments which prepare punctually prepared advanced therapy medicinal products shall keep data enabling the identification of samples of tissues, cells, blood…

Read More »

Article R5121-201-6 of the French Public Health Code

Before administering the punctually prepared advanced therapy medicinal product, the health professional in the health establishment must ensure that the information required for the traceability of the medicinal product appears on the labelling of its immediate packaging. After administering it, the health professional draws up an administration record which includes the following information: 1° The name of the advanced therapy medicinal product prepared on an ad hoc basis; 2° The…

Read More »

Article R5121-201-7 of the French Public Health Code

The data referred to in II and III of Article R. 5121-201-5 and a copy of the administration record referred to in Article R. 5121-201-6 shall be kept by the establishments referred to in Article R. 5121-201-5 for at least thirty years after the expiry date of the advanced therapy medicinal product prepared on an ad hoc basis.

Read More »

Article R5121-201-8 of the French Public Health Code

In the event of interruption or cessation of activity of an establishment or organisation mentioned in article L. 4211-9-1, the data relating to the traceability of advanced therapy medicinal products prepared on an ad hoc basis are transferred to the establishment or organisation authorised under the same article, with which it has set up agreements or procedures in application of I of article R. 4211-42. In the event of interruption…

Read More »

Article R5121-202 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé shall draw up the list of medicinal products, known as medicinal products for officinal use, which the dispensing pharmacist may present for direct access to the public under the conditions set out in article R. 4235-55. It is published on the Agency’s website. At the request of the marketing authorisation holder or the person…

Read More »

Article R5121-203 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé may, by reasoned decision, refuse to include a medicinal product on the list referred to in Article R. 5121-202 for any public health reason, in particular when the benefit/risk balance of the medicinal product as defined in the first paragraph of Article L. 5121-9 is being reassessed.

Read More »

Article R5121-204 of the French Public Health Code

The Director General of the Agence nationale de sécurité du médicament et des produits de santé may suspend or remove the registration of a medicinal product from the list provided for in article R. 5121-202 if the conditions laid down in this article are no longer met or for any public health reason, in particular when the benefit/risk balance of the medicinal product as defined in the first paragraph of…

Read More »

Article R5121-206 of the French Public Health Code

The detailed rules for the application of sections 1 to 12 of this chapter are determined as necessary, after obtaining the opinion of the Director General of the Agence nationale de sécurité du médicament et des produits de santé, by order of the Minister for Health. This specifies, where appropriate, the information to be included on the packaging of proprietary medicinal products intended for health establishments and the distinctive signs…

Read More »

Article R5121-207 of the French Public Health Code

The application for authorisation or renewal of authorisation provided for in 12° and 13° of Article L. 5121-1 shall be sent by registered post with acknowledgement of receipt or lodged against receipt with the Director General of the Agence nationale de sécurité du médicament et des produits de santé by the establishments and organisations authorised to carry out the activities mentioned in Article R. 4211-16 . The application must be…

Read More »

Contact a French lawyer now

Contact a French Business Lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.